Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
Stopped This study was terminated early due to lack of adequate response, and did not move to the Phase II portion of the study
Conditions
- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- DRUG: Cytarabine
- DRUG: Milademetan Tosylate
- DRUG: Venetoclax
Sponsor
M.D. Anderson Cancer Center
Collaborators